RTI Biologics (NASDAQ:RTIX), based in Florida, has a checkered history in the medical device space as a provider of natural tissues and technologies used in a variety of orthopedic and other surgical procedures. The company announced what is clearly a potentially transformational acquisition of privately-held Pioneer Surgical Technology on June 12th, but the market barely responded. While this could be a game-changer for RTIX if the deal achieves the primary goals of diversifying the product portfolio and customer base while raising margins and growth, there are several reasons that investors will not rush in to buy the story.
RTIX was formed in 1997 as a subsidiary of the University of Florida Tissue Bank, began operations in 1998...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|